Tenax Therapeutics, Inc. (TENX)
NASDAQ: TENX · Real-Time Price · USD
4.770
-0.090 (-1.85%)
Nov 20, 2024, 4:00 PM EST - Market closed
Tenax Therapeutics Employees
As of December 31, 2023, Tenax Therapeutics had 6 total employees, including 5 full-time and 1 part-time employees. The number of employees decreased by 2 or -25.00% compared to the previous year.
Employees
6
Change (1Y)
-2
Growth (1Y)
-25.00%
Revenue / Employee
n/a
Profits / Employee
-$2,426,764
Market Cap
16.26M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Marinus Pharmaceuticals | 166 |
| Retractable Technologies | 151 |
| Flora Growth | 108 |
| Lifeward | 108 |
| Cara Therapeutics | 55 |
| Nephros | 31 |
| Innovative Eyewear | 11 |
| Aprea Therapeutics | 7 |
TENX News
- 5 days ago - Tenax Therapeutics, Inc. (TENX) Guggenheim Healthcare Innovation Conference (Transcript) - Seeking Alpha
- 8 days ago - Tenax Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 20 days ago - Tenax Therapeutics to Present at the Guggenheim Healthcare Innovation Conference - GlobeNewsWire
- 3 months ago - Tenax Therapeutics Announces Oversubscribed $100 Million Private Placement - GlobeNewsWire
- 6 months ago - Tenax Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 7 months ago - Tenax Therapeutics Announces New U.S. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF) - GlobeNewsWire
- 8 months ago - Tenax Therapeutics to Host KOL Event: “LEVEL Setting: the Scientific Rationale for Levosimendan as a Potential First Treatment for PH-HFpEF, and the Ongoing Phase 3 LEVEL Study” - GlobeNewsWire
- 8 months ago - Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial Results - GlobeNewsWire